Please assess the completion status of the following clinical trial:

Trial Title: Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participants were male or female aged between 2 and 18 years (inclusive).~* Participants had a documented history of Dravet Syndrome that was not completely controlled by current antiepileptic drugs.~* Participants took one or more antiepileptic drugs at a dose that had been stable for at least four weeks.~* All medications or interventions for epilepsy (including ketogenic diet and vagus nerve stimulation) were stable for four weeks prior to screening and participants were willing to maintain a stable regimen throughout the study.~Key Exclusion Criteria:~* Participants had clinically significant unstable medical conditions other than epilepsy.~* Participants had clinically relevant symptoms or a clinically significant illness in the four weeks prior to screening or randomization, other than epilepsy.~* Participants were currently using or had in the past used recreational or medicinal cannabis or synthetic cannabinoid based medications (including Sativex®) within the three months prior to study entry and were unwilling to abstain for the duration for the study.~* Participants had any known or suspected hypersensitivity to cannabinoids or any of the excipients of the investigational medicinal products.~* Participants had been part of a previous clinical trial involving another investigational product in the previous six months.~* There were plans for the participants to travel outside their country of residence during the study.~* Participants previously randomized into this study. In particular, participants who participated in Part A of the study could not enter Part B.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- GWP42003-P 20 mg/kg/day Dose (Type: EXPERIMENTAL): Participants received 20 mg/kg/day of GWP42003-P administered orally, half in the morning and half in the evening. Participants titrated GWP42003-P to 20 mg/kg/day over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day) period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo (0 mg/mL CBD), volume-matched to the 20 mg/kg/day dose level, administered orally, half in the morning and half in the evening. To maintain the blinded aspect of the study, participants titrated the placebo dose over 11 days and remained at this dose for the 12-week maintenance period. If the participant did not immediately enter the OLE study, the maintenance period was followed by a 10-day taper (10% per day of the matched dose) period.

Based on this trial design, predict the completion outcome and termination type (if applicable).